Stroke treatment window could expand to 72 hours in new trial
NCT ID NCT06954155
First seen Nov 19, 2025
Summary
This study tests whether the clot-busting drug tenecteplase can help people who have had a stroke 24 to 72 hours earlier. Currently, such drugs are only given within a few hours. The trial will compare tenecteplase to standard care (blood thinners) in 330 adults with blocked brain arteries. The goal is to see if more patients can live independently at 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing tiantan hospital
RECRUITINGBeijing, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenecteplase (a clot-busting drug given as a single injection)
What this could lead to
If it works, this could extend the time window for treating strokes from hours to days, helping more people recover with less disability.
What could go wrong
This is an early phase 3 trial with only 330 participants. The drug may not improve outcomes and carries a risk of bleeding in the brain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.